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EgyptianAbstract Aim of the work: The aim of the present work was to determine the prevalence of infec-
tions in a cohort of Egyptian Systemic lupus erythematosus (SLE) patients and to describe their
sites and relation to clinical characteristics, laboratory features and disease activity.
Patients and methods: Medical records of 250 Egyptian SLE patients attending the Rheumatol-
ogy department, Cairo University hospitals were reviewed retrospectively for the clinical and
laboratory features, SLE disease activity index (SLEDAI) and treatment received.
Results: Infection was found in 119 (47.6%) patients, with bacterial infection being the common-
est in 99 (83%) followed by fungal infection in 30 (25%) and viral infection in 22 (18.5%). The com-
monest site of infection was the skin (37%) followed by the urinary tract (31%) and chest (19%). In
SLE patients with infection there was a signiﬁcant increase in the frequency of malar rash
(p= 0.001), photosensitivity (p= 0.01), oral ulcers (p< 0.001), alopecia (p= 0.017) and
Raynauds (p= 0.017) compared to those without infection. Pulmonary and neuropsychiatric man-
ifestations were also signiﬁcantly increased in those with infection (p= 0.001 and p< 0.001). A sig-
niﬁcantly higher number of patients with infection were receiving pulse steroids (p= 0.016),
cyclophosphamide (p= 0.011) and a higher oral prednisolone dose (p= 0.03). The SLEDAI
was signiﬁcantly higher (26.02 ± 8.23) in those with infection compared to those without
(15.57 ± 6.43) (p< 0.001). C-reactive protein (CRP) was signiﬁcantly higher in those with infec-
tion (p< 0.001). On performing a logistic regression analysis, only SLEDAI (p< 0.001) and
CRP (p< 0.001) were signiﬁcant predictors of infection.
Conclusion: Disease activity and CRP are important predictors for infection in SLE patients.
 2014 Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Rheumatic Diseases.1. Introduction
Systemic lupus erythematosus (SLE) is a heterogeneous multi-
system autoimmune disease [1] with protean manifestations,
172 S. Fakhreldin et al.which may range from relatively minor skin and joint manifes-
tations to severe life-threatening major organ involvement [2].
SLE is the second most common autoimmune disorder (after
thyroid disease) in childbearing age women [3]. Many key
events have been implicated in the pathogenesis of SLE such
as cytokine overproduction [4,5], oxidative stress [6] and
apoptosis [7].
Several comorbidities such as metabolic syndrome [8], dysl-
ipidemia and atherosclerosis [9] could lead to functional dis-
ability, impaired quality of life and signiﬁcantly affect the
disease activity and damage. Survival rates for SLE patients
have improved greatly with the ability to treat disease-speciﬁc
manifestations and to lessen the impact of comorbid condi-
tions [10], but a three- to ﬁve-fold increased risk of death
remains compared with the general population [3].
Infections are among the most important causes of morbid-
ity and mortality in SLE patients [11]. Despite the availability
of newer therapeutic measures to improve clinical outcome in
SLE patients, the incidence of infections as a cause of morbid-
ity and mortality has not changed over the past 30 years [12],
and infection is still considered as one of the leading causes
of morbidity and mortality in SLE patients [13]. Infection is
responsible for approximately 25% of all deaths in patients
with SLE, making it a leading cause of mortality in SLE
[14]. The reasons which may explain the high incidence of
infection in SLE are immunosuppressive therapy and immune
disturbances of lupus itself, also infections can mimic disease
ﬂares in established SLE, leading to confusion over the diagno-
sis and appropriate treatment [13,15]. There are several specu-
lations on the contributory role of microbes in the induction
and reactivation of chronic inﬂammatory and autoimmune
conditions [16,17], although the reciprocity between pathogen
and immune system dysregulation has not yet been clearly
determined. These assumptions have largely emerged from
the production of various autoantibodies during the course
of many types of infections [2]. The main etiologic infectious
agents in SLE patients are common bacterial pathogens, espe-
cially capsulated ones and the most commonly affected organs
are lung, skin, bladder, brain and systemic infections [12].
The aim of the present work was to determine the preva-
lence of infections in a cohort of Egyptian Systemic lupus ery-
thematosus (SLE) patients and to describe their sites and
relation to clinical characteristics, laboratory features and
disease activity.
2. Patients and methods
2.1. Patients
Medical records of all Egyptian SLE patients attending the
Rheumatology and Rehabilitation Department of Cairo
University Hospitals during a 6 month period in 2011 were
reviewed retrospectively for the demographic information,
clinical features of the disease, immune proﬁle, laboratory
features, systemic lupus disease activity index (SLEDAI)
and medical treatment. All of the patients fulﬁlled the
updated American College of Rheumatology (ACR) revised
criteria for the classiﬁcation of SLE [18]. The study has been
approved by local ethics committee and it conforms to the
standards currently applied in the Cairo University Teaching
Hospitals.The patients were classiﬁed into two groups:
Group 1: Patients who experienced at least one episode of
infection and admitted to hospital or examined at least once
by one of our physicians during infection episode. This group
was classiﬁed as the infection group. The site of infection was
also recorded.
Group 2: Those patients who had no relevant infectious epi-
sode and did not require hospital consultations or admission
due to infection related complications.
Demographic features including age, sex, and time elapsed
from SLE diagnosis were collected from medical charts.
Detailed clinical characteristics and laboratory features were
recorded. Results of immune proﬁle including the antinuclear
antibodies (ANA), anti-dsDNA and complement levels were
also documented. The use of corticosteroids or immunosup-
pressive drugs was reviewed. The disease activity was assessed
and recorded using Systemic Lupus Erythematosus disease
activity index (SLEDAI) [19] at time of infection in group 1
and at the last visit for those in group 2.
Statistical analysis: Data were presented as numbers, per-
centage, mean ± SD. Mann–Whitney test was performed to
compare between two non parametric groups. Chi square
Pearson’s test was performed to detect associations between
categorical variables. Multiple linear regression analysis was
performed to ﬁnd the clinical, laboratory and medication pre-
dictive factors for infection in SLE.
3. Results
This study included 250 Egyptian SLE patients; their mean age
was 27.38 ± 7.74 years with disease duration of
6.07 ± 4.08 years. They were 226 females and 24 males. Group
1 included 119SLEpatientswith infection andGroup 2 included
131 patients without infection. The clinicalmanifestations,med-
ications received and disease activity are presented in Table 1.
The laboratory features of the studied patients are shown in
Table 2.
The SLE patients with infection were 111 females and 8
males with a mean age of 27.77 ± 8.30 years; their disease
duration was 6.45 ± 4.21 years. SLE patients without infec-
tion were 115 females and 16 males with a mean age of
27.02 ± 7.11 years and disease duration of 5.72 ± 3.95 years.
Regarding the causative organisms, in the infection group,
bacterial infection was the commonest as it was detected in
99 patients (83%) with staphylococcus aureus being the com-
monest, followed by fungal infection detected in 30 (25%)
and viral infection in 22 (18.5%) patients. Combined infection
with more than one causative organism was found in 34
patients (28.5%) while single pathogen infection was found
in 85 patients (71.4%).
Regarding the sites of infection, the commonest site of infec-
tion was the skin (37%) followed by the urinary tract (31%) and
chest (19%). Other sites with less frequency of affection were
blood in 11%, vagina and knee joints in 9.2% each, oral cavity
in 8.4%andother sites (e.g., Ear and nose) in 5%.The frequency
of occurrence of infection at different sites is graphically pre-
sented in Fig. 1.
There was no signiﬁcant difference in the age (p= 0.44),
gender (p= 0.14) or disease duration (p= 0.16) between the
SLE patients with and without infection. A signiﬁcant differ-
ence was found between the two groups regarding the disease
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manifestations as presented in Table 1. Secondary vasculitis
was present in 5/119 (4.2%) of the SLE patients with infection
while it was not present in those without infection. On the
other hand, deep venous thrombosis occurred in 2 patients
without infection.
Table 2 shows the laboratory features of the SLE patients
with and without infection. On performing a logistic regression
analysis, only SLEDAI (p< 0.001) and CRP (p< 0.001) were
signiﬁcant predictors of infection.4. Discussion
Infections are one of the leading causes ofmorbidity andmortal-
ity in patients with SLE [20–22]. Infection is responsible for
approximately 25% of all deaths in SLE patients, making it a
leading cause of mortality [14], on the other hand infections
are known to be major environmental factor that has been
shown to be highly associated with the development of SLE
especially Epstein–Barr virus (EBV) infection [17,23]. In-spite
of the variations in studies’ designs, durationof follow-up,meth-
ods of patients’ selection, the rate of infection in lupus patients
was always found to be high. In our study it was found to be
47.6%, which is comparable to what was noted by other investi-
gators (58.79%) [24], (32%) [25] and (36%) [26].
Skin infection was the most common site as it occurred in
37% of the infection group; other common sites of infection
included the urinary tract in 31%, chest in 19%, blood in
11%, vagina and knee joints in 9.2% each, oral cavity in
8.4% and other sites (e.g., Ear and nose) in 5%. The higher
prevalence of skin and urinary tract (UT) infection in ourTable 1 Clinical characteristics, medications received and disease a
Clinical manifestations No (%) SLE patients (n= 250)
With infection (n= 119)
Photosensitivity 63 (52.94)
Malar rash 87 (73.11)
Oral ulcers 74 (62.18)
Alopecia 82 (68.91)
Dry eyes and mouth 12 (10.08)
Myalgia/myositis 14 (11.76)
Antiphospholipid syndrome 15 (12.61)
Renal 62 (52.10)
Cardiac 24 (20.17)
Pulmonary 73 (61.34)
Neuropsychiatric 65 (54.62)
Raynaud’s 34 (28.57)
Arthritis 97 (81.51)
Medication used
HCQ 87 (73.11)
Azathioprine 76 (63.87)
Pulse corticosteroids 90 (75.6)
Pulse cyclophosphamide 50 (42)
Methotrexate 9 (7.5)
Mycophenolate mofetil 8 (6.7)
Oral prednisolone mg/daya 19.77 ± 9.29
SLEDAI a 26.02 ± 8.23
a Presented as mean ± SD, APS: Antiphospholipid syndrome, HCQ: Hy
Activity Index. S = Signiﬁcant, NS = Non signiﬁcant.patients was also reported by Zonana-Nacach et al. [25] where
UT infection was found in 26% and skin infection in 23% of
the total infections. The role of bacterial pathogens in infection
in lupus patients [12,24,27] was also documented in our study
and bacterial infection was found in 83% of the cases most of
which were Staphylococcus aureus. Increased relapse rate was
found in SLE patients with Staphylococcus aureus infection
compared to those without [28].
In the current study, a signiﬁcant difference was found
between the two groups regarding many clinical manifestations
as oral ulcers and neuropsychiatric as well as the CRP and the
SLEDAI, however after regression analysis only CRP
(p< 0.001) and SLEDAI (p< 0.001) were found to be signif-
icant predictors of infection. Such results may indicate that ele-
vated CRP can be used as a marker of active infection in SLE
with high speciﬁcity and it conﬁrms the results of several
reports about the importance of CRP as a biomarker of infec-
tion in lupus patients [17,29–31].
On the other hand, elevated SLEDAI is an independent risk
factor for mortality in patients with SLE [22] and its associa-
tion with infection in this study even after regression analysis
(p< 0.001) was not surprising. In our opinion SLEDAI is a
compound risk factor as active disease may be associated with
chest complication, weak muscles, complement deﬁciency,
extensive need for immunosuppressive medications, bed ridden
patients and prolonged hospital stay, and all of these factors
can be considered as risk factors for infection and this is in line
with what was stated by Al-Rayes et al. [24] as they reported
that the high incidence of infections in SLE patients may be
attributed to the multiple intrinsic and extrinsic risk factors
including deﬁciency of complement (C3 and C4), disease activ-
ity, renal impairment, use of glucocorticoid and cytotoxicctivity of the SLE patients with and without infection.
p Sig.
Without infection (n= 131)
48 (36.64) 0.01 S
68 (51.91) 0.001 S
47 (35.88) <0.001 S
71 (54.2) 0.017 S
16 (12.21) 0.59 NS
11 (8.4) 0.38 NS
11 (8.4) 0.28 NS
68 (51.91) 0.98 NS
16 (12.21) 0.09 NS
52 (39.69) 0.001 S
26 (19.85) <0.001 S
21 (16.03) 0.017 S
97 (74.05) 0.16 NS
84 (64.12) 0.13 NS
83 (63.36) 0.93 NS
36 (27.4) 0.016 S
34 (25.9) 0.011 S
6 (4.5) 0.46 NS
10 (7.6) 0.97 NS
17.14 ± 9.11 0.03 S
15.57 ± 6.43 <0.001 S
droxychloroquine, SLEDAI: Systemic Lupus Erythematosus Disease
Figure 1 Frequency of distribution of site of infection in SLE patients.
Table 2 Laboratory investigations of the SLE patients with and without infection.
Laboratory investigations mean ± SD or No (%). SLE patients (n= 250) p Sig.
With infection (n= 119) Without infection (n= 131)
ESR (mm/hr) 56.79 ± 42.38 56.42 ± 34.86 0.94 NS
WBCs (·103/mm3) 8.58 ± 6.54 8.16 ± 6.39 0.61 NS
Hemoglobin (g/dl) 11.40 ± 1.78 11.28 ± 2.02 0.65 NS
Platelet (·103/mm3) 275.49 ± 86.11 267.9 ± 85.96 0.49 NS
Creatinine (mg/dl) 0.83 ± 0.61 0.79 ± 0.74 0.66 NS
Albumin (g/dl) 3.743 ± 0.68 3.74 ± 0.56 0.97 NS
AST (U/L) 28.61 ± 34.0 25.84 ± 19.26 0.42 NS
ALT (U/L) 23.59 ± 16.64 25.22 ± 17.61 0.45 NS
C3 (mg/dl) 68.06 ± 46.62 70.4 ± 41.8 0.67 NS
C4 (mg/dl) 15.07 ± 15.32 14.76 ± 16.57 0.88 NS
Positivity C-reactive protein 74 (62.8) 2 (1.53) <0.001 S
ANA 114 (95.8) 126 (96.18) 0.88 NS
Anti-DNA 66 (55.46) 73 (55.73) 0.97 NS
Anti-Ro 63 (52.94) 58 (44.27) 0.17 NS
Anti-La 27 (22.69) 20 (15.27) 0.13 NS
Anticardiolipin 16 (13.45) 13 (9.92) 0.39 NS
ESR: Erythrocyte sedimentation rate, Hb: Hemoglobin, WBC: White blood cells, AST: Aspartate transaminase, ALT: Alanine transaminase,
C: Complement, ANA: Antinuclear antibodies, Anti-ds-DNA: Anti-double stranded DNA.
174 S. Fakhreldin et al.drugs. Also Duffy et al. [32] found that by logistic regression
analysis, infection was signiﬁcantly associated with disease
activity (p= 0.005), but not with disease duration or
prednisone dosage, while Navarro-Zarza et al. [33] reported
that risk factors for infection include disease activity, use of
immunosuppressants, disease duration, and length of hospital
stay.
In fact, different studies may show different risk factors of
infection in lupus patients, however in most of these studies
disease activity is a common risk factor [25,26,30,34]. Even
Zonana-Nacach et al. [25] reported that at infection onset
77% of patients had elevated disease activity, with a meanSLEDAI score of 6.1 and that the variables signiﬁcantly
associated with infection were the presence of disease activity,
SLEDAI score, renal activity, prednisone dose and receiving
cyclophosphamide; however, the only variable associated with
infection in the multivariate analyses was a SLEDAI score of 4
or higher.
It could be concluded that high disease activity in lupus is
an important predictor for infection. Every attempt should
be done to control the disease activity using the least possible
doses of immunosuppressive drugs with close monitoring of
patients to reduce the risk of increased morbidity and mortal-
ity in lupus patients due to infection.
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